Paradromics is developing high-volume bidirectional data streaming capabilities between brains and computers. Our neural interface technologies will initially be used to help physically disabled patients reconnect with the outside world – with infinite possibilities beyond.
Paradromics was founded in 2015 by a team of engineers and neuroscientists, received early support from both NIH and DARPA, and is currently backed by venture capital.
Matt Angle, PhD, Founder and CEO
Matt has a background in nanotechnology and neuroscience. As a graduate student at the Max Planck Institute for Medical Research and as a post-doctoral researcher at Stanford University, he was immersed in the development and the study of neural recording technologies. In the course of his research, he and his collaborators invented a new, powerful way of interfacing with the brain. As CEO of Paradromics, Matt has assembled a team of physicists, electrical, software, and mechanical engineers to turn a promising technology into a robust, marketable platform.
Thomas Krummel, MD, Chairman
Over the last 20 years, Thomas has been a pioneer in the application of information technology to simulation-based surgical training and surgical robotics. Thomas is a recipient of one of the first NIH Phased Innovation R21/R33 programs to develop collaborative simulation-based surgical training systems. For his work in this area and in surgical robotics, he has received two ComputerWorld Smithsonian Awards. Thomas is co-director of the Stanford Byers Center for Biodesign; Chairman of the Fogarty Institute for Innovation; President of the International Scientific Committee at IRCAD, University of Strasbourg, France; and is former Chair of the Department of Surgery at Stanford.
Enke Bashllari, PhD, Board Member
Enke is a neuroscientist and venture investor, passionate about radical innovation in healthcare driven by novel models of care delivery and frontier technology applications to medicine. She is the Managing Director of Arkitekt Ventures, an healthcare investment fund via which she advises and supports exceptional technical founders. Prior to that, she worked on a private-market investment strategy for an international family office supporting direct investments in early to mid stage companies across the healthcare & life-science spectrum. Enke earned her PhD at Columbia University Medical Center, and holds an MBA from Harvard Business School where she was awarded the Kaplan Fellowship for outstanding life-science business professionals.
Adam A. Kablanian, Board Member
Adam was most recently the Chairman and CEO of PlasmaSi, which recently sold to Aixtron SE. PlasmaSi developed a thin-film deposition technology based on very low temperature silicon nitride Plasma Enhanced Chemical Vapor Deposition (PECVD). Adam was instrumental in focusing that team to turn an exciting technology into a viable commercial system. Before his time at PlasmaSi, Adam was the CEO of Memoir Systems, a venture-backed memory IP company that was acquired by Cisco in October 2014. Before that, he served as the Chairman of the Board (1996-2008) and Chief Executive Officer (1996-2007) of Virage Logic, a company he co-founded in 1996 and subsequently took public on NASDAQ (VIRL).
Ron Kelly, Board Member
Ron is President and CEO of Ambature, Inc., which develops A-axis thin film technology for application in the high temperature superconductor market. Prior to joining Ambature, Ron was President and CEO of healthcare company Medicalis Corporation and served in board and management positions for Mitra Imaging Inc. and TLC The Laser Center Inc. Coming from a law background, Ron has extensive experience in negotiating technology licensing with large multinational corporations. He was Adjunct Professor in Contract Law at The University of Western Ontario for 2 years and, over his career, has been very active in working with the US and Canadian governments to help them understand the value of technology as part of creating greater quality and efficiencies in the healthcare industry.
Scientific Advisory Board
Paradromics benefits from close ties and collaboration with world-class research labs.